View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Kinaxis
11 December 2019

Kinaxis Named a Leader for Third Time

Kinaxis Inc, a frontrunner in empowering individuals to make confident supply chain decisions, has been named a leader in the Nucleus Research 2019 Control Tower Technology Value Matrix for the third year running.

As one of only four vendors in the leaders’ quadrant, Kinaxis also ranks highest on the ‘Greater Usability’ axis with its leading RapidResponse® platform and applications that cover integrated business planning, demand planning, supply planning, inventory planning, production planning and machine learning.

When ranking technology solutions in its Control Tower Technology Value Matrix 2019, Nucleus Research cites machine learning and AI algorithms as key capabilities. Specifically, Nucleus mentions the ability to review historical performance data to provide a larger contextual picture when exceptions in the supply chain network arise as cornerstone functionality in their ranking.

The research firm named Kinaxis a leader for the value it delivers to customers with its suite of planning applications on its RapidResponse platform and its unique concurrent planning technique. Using RapidResponse, planners have a real-time view of their organization’s entire ecosystem, eliminating silos between functional groups within a company, as well as an extended view outside the company’s four walls.

With customers and partners in every region around the globe, Kinaxis provides a unique concurrent end-to-end planning solution for a wide range of vertical markets, including aerospace and defence, automotive, consumer products, high-tech and electronics, industrial and life sciences.

According to the report, “With practical applications of technology and ease of use as central tenets of the vendor’s strategy, Nucleus found that the approach resonates with customers that have often been bogged down with legacy solutions and internal silos. As Kinaxis continues to expand its solution to deliver greater functionality and more capabilities in supply chain execution, Nucleus expects the vendor’s position in future versions of the Value Matrix to improve.”

The 2019 Control Tower Value Matrix is an assessment of the state of the control tower market and ranked 12 vendors based on the functionality and product usability of current technology solutions and value that customers realize from these capabilities. Since its establishment in 2017, Kinaxis has consecutively placed in the leaders’ quadrant and furthest along the ‘Greater Usability’ axis of the Nucleus Research Control Tower Value Matrix.

“We’re committed to creating a solution that makes planners’ lives easier and gives executives the visibility they need across the entire supply chain,” said John Sicard, CEO, Kinaxis. “Our continued investments in network visualizations, data integration, user experience and platform extensibility strengthens the Kinaxis control tower capabilities and gives companies the transparency, agility and efficiency they need to eliminate waste across their supply chains.”

For more information or to view the full report, please fill out the enquiry form attached to this page.

Supply chains in the life sciences sector are about as complex as they come. As biomedical advancements trigger a continuous stream of new product introductions,...
Using a single planning platform, Kinaxis unifies your supply chain planning to streamline your processes, break down silos and plan concurrently across every area of...
As a company with a 125-year history of improving the health and well-being of people worldwide, MSD (known as Merck & Co in the US...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology